1 / 9

CD-RAP and Palovarotene

CD-RAP and Palovarotene. Lab Meeting 3/18/2014. Palovarotene. A retinoic acid receptor gamma (RAR γ ) agonist Inhibits cartilage formation During development, new bone formation is stimulated by a drop in retinoid signaling

jessamine-crawford
Download Presentation

CD-RAP and Palovarotene

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. CD-RAP and Palovarotene Lab Meeting 3/18/2014

  2. Palovarotene • A retinoic acid receptor gamma (RARγ) agonist • Inhibits cartilage formation • During development, new bone formation is stimulated by a drop in retinoid signaling • RARγ agonists maintain retinoid signaling preventing new bone formation • Has been shown to prevent HO formation

  3. A B n = 16 0 0 1.47 1.47 2.94 2.94 n = 8 n = 9 Palovarotene (mg/kg) Palovarotene (mg/kg) C n = 8 n = 9 n = 16

  4. CD-RAP • CD-Rap is expressed during chondrogenesis • A plasma biomarker for cartilage formation • Observed to be elevated in patients with: • Neurofibromatosis type I • Rheumatoid Arthritis • During fracture healing • Marathon runners

  5. Rationale • A circulating biomarker provides an additional metric for the efficacy of a treatment • A particular drug may not improve function but may result in lower biomarker levels suggesting that the class of drug may hold promise

  6. Methods • Plasma samples from mice and patients • ELISA • Mouse: Kit from CUSABIO • Human: Kits from Roche and CUSABIO

  7. Palovarotene treatment results in lower CD-RAP levels * *

  8. Human CD-RAP ELISA

  9. Conclusion and continuing work • CD-RAP shows promise as a circulating biomarker for HO formation • Repeat mouse CD-RAP ELISA • Increase number of samples to 8 at each time point • Repeat human CD-RAP ELISA • More samples for each group • Repeat with first kit tested at higher plasma concentration

More Related